Design, validation, and development of novel peptidomimetic therapeutics targeting SARS-CoV-2 replication.

Grant number: IPA/2020/000285

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    SERB India
  • Principal Investigator

    Dr. Arockiasamy Arulandu
  • Research Location

    India
  • Lead Research Institution

    International Centre for Genetic Engineering and Biotechnology (ICGEB) New Delhi
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

New or repurposed antivirals against valid viral targets, viricidal coatings

Publicationslinked via Europe PMC

Modes of Binding of Small Molecules Dictate the Interruption of RBD-ACE2 Complex of SARS-CoV-2.

Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro.